GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (FRA:2Q5) » Definitions » Additional Paid-In Capital

Renovaro (FRA:2Q5) Additional Paid-In Capital : €406.92 Mil(As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Renovaro Additional Paid-In Capital?


Renovaro's quarterly additional paid-in capital declined from Sep. 2023 (€281.11 Mil) to Dec. 2023 (€276.34 Mil) but then increased from Dec. 2023 (€276.34 Mil) to Mar. 2024 (€406.92 Mil).

Renovaro's annual additional paid-in capital increased from Jun. 2021 (€220.43 Mil) to Jun. 2022 (€262.03 Mil) and increased from Jun. 2022 (€262.03 Mil) to Jun. 2023 (€268.18 Mil).


Renovaro Additional Paid-In Capital Historical Data

The historical data trend for Renovaro's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Additional Paid-In Capital Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 199.80 204.68 220.43 262.03 268.18

Renovaro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 268.05 268.18 281.11 276.34 406.92

Renovaro Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Renovaro Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Renovaro's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro (FRA:2Q5) Business Description

Industry
Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.

Renovaro (FRA:2Q5) Headlines

No Headlines